跳到正文
原文
NEJM 新英格兰医学杂志· Ferdinandos Skoulidis Myung-Ju Ahn Shirish Gadgeel Sanjay Popat Niels Reinmuth Bianca van Veggel Farastuk Bozorgmehr Victoria J. Bray Michael Duruisseaux Wade T. Iams Julien Mazieres Laura Bonanno Lore Decoster Jiaxin Niu Marcos Pantarotto Carlos Henrique Andrade Teixeira Sevim Uzun Bo Wang Bryan A. Chan Enriqueta Felip Molly S.C. Li Hiroaki Akamatsu Kristof Cuppens Tae Min Kim Martin Reck Youyou Hu Sarah M. Shagan Mark T. Lin Uyi Osaghae Tien Hoang Felice Wu Raymond Meng Michael S. Mathisen and Benjamin J. Solomon·· 26 天前AI 评分24

Divarasib对比Sotorasib或Adagrasib用于KRAS G12C突变非小细胞肺癌的III期临床试验结果

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

AI 导读

Divarasib在KRAS G12C突变非小细胞肺癌患者中显示出更优的无进展生存期(PFS)和总生存期(OS)数据(HR=0.82,95% CI 0.73-0.93。

来源:NEJM 新英格兰医学杂志 · nejm.org